Short answer
AbbVie Inc (ABBV) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $17.0B (up 10.2% year over year) with net income of $3.6B.
Q2 2026 key financials · XBRL
- Revenue
- $17.0B
- +10.2% YoY · +13.3% QoQ
- Net income
- $3.6B
- +285.2% YoY · +419.9% QoQ
- Operating margin
- 37.9%
- EPS (diluted)
- $2.03
- +290.4% YoY · +420.5% QoQ
Source: XBRL data from the AbbVie Inc (ABBV) Q2 2026 10-Q on SEC EDGAR. USD.
AbbVie Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $16,990M, up 10.2% YoY from $15,423M
- Gross margin 75% vs 72% YoY; effective tax rate 15% vs 39%
- Best performer: Skyrizi revenue $5,505M, up 24.4% YoY
- Worst performer: Humira revenue $756M, down 35.9% YoY
- Operating cash flow $7,265M vs $6,788M; dividends $6.2B and buybacks $1.1B in six months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AbbVie Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.